Effect of total parenteral nutrition with different lipid emulsions of human monocyte and neutrophil functions.
Parenteral nutrition (TPN) with lipid emulsions is claimed to be associated with impaired monocyte (M) and neutrophil (N) functions. Long-chain triglycerides (LCT) and a mixture containing 50% medium-chain triglycerides (MCT) and 50% LCT, currently used in nutritional therapy with TPN, were evaluated for their ex vivo effects on human N and M chemotaxis, phagocytosis, bacterial killing, and oxidative metabolism by nitroblue tetrazolium reduction test. Cell functions were examined in a randomized, crossover, blind trial in 10 malnourished patients with gastric cancer. Prior to the operation (2 wk), central TPN (40 kcal/kg) with 25% of caloric energy provided as LCT or MCT/LCT emulsion was infused over 48 h. After the crossover period fat-free TPN was given over 48 h. Function tests were done for N and M before and after each lipid emulsion infusion. Every cell function test performed for each patient was controlled by another test done in healthy adult volunteers and the results were compared with the normal range of values previously established for a healthy adult population. All the patients completed the studies without complications. Crossover validity was statistically established. Bacterial killing was the only function reduced in neutrophils after LCT emulsion (% killed bacteria = 79.0 +/- 8.5 versus 67.4 +/- 19.2; P < 0.05), although this function remained within the normal range values in 80% of the patients. In conclusion, the lipid emulsions did not affect any monocyte functions and only moderately decreased neutrophil bacterial killing.
Waitzberg
D L
DL
Department of Gastroenterology, University of São Paulo Medical School Brazil.
Bellinati-Pires
R
R
Salgado
M M
MM
Hypolito
I P
IP
Colleto
G M
GM
Yagi
O
O
Yamamuro
E M
EM
Gama-Rodrigues
J
J
Pinotti
H W
HW
D000368:Aged; D001770:Blood Bactericidal Activity; D002634:Chemotaxis, Leukocyte; D002149:Energy Intake; D005217:Fat Emulsions, Intravenous / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000502:physiology*; D009504:Neutrophils / Q000502:physiology*; D009580:Nitroblue Tetrazolium; D010084:Oxidation-Reduction; D010289:Parenteral Nutrition, Total / Q000009:adverse effects*; D010587:Phagocytosis; D011446:Prospective Studies; D014280:Triglycerides / Q000008:administration & dosage / Q000009:adverse effects
D005217:Fat Emulsions, Intravenous; D014280:Triglycerides; D009580:Nitroblue Tetrazolium